Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Siemens, Krelo in Graves' disease test pact:

This article was originally published in Clinica

Executive Summary

Siemens Medical Solutions Diagnostics has inked a deal with German IVD company KreLo GmbH Medical Diagnostics to develop an assay used in the differential diagnosis of Graves' disease, a condition that affects around 32 million people worldwide. The assay, designed to detect stimulating TSH receptor autoantibodies (TRAb), will be the first test of its kind to feature Krelo's proprietary TRAb biomarkers. Graves' disease is one of the most common forms of hyperthyroidism. It is characterised by the presence of TSH receptor autoantibodies, which mimic the activity of TSH, resulting in the elevated production of thyroid hormone. If left untreated, Graves' disease can lead to miscarriage, birth defects, thyroid eye disease and can be life-threatening.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT045656

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel